Vose JM. Mantle cell lymphoma: 2013 Replace on prognosis, risk-stratification, and medical administration. Am J Hematol. 2013;88:1082–8.
Jain N, Mamgain M, Chowdhury SM, Jindal U, Sharma I, Sehgal L, et al. Past Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CAR T-cells, and novel brokers. J Hematol Oncol. 2023;16:99.
Avyakta Kallam M, Vose JM. Present remedies in mantle cell lymphoma. Oncology. 2023;37:326–33.
Bukhari A, El Chaer F, Koka R, Singh Z, Hutnick E, Ruehle Okay, et al. Fast relapse of enormous B-cell lymphoma after CD19 directed CAR-T-cell remedy because of CD-19 antigen loss. Am J Hematol. 2019;94:E273–E5.
Mathur R, Sehgal L, Braun FK, Berkova Z, Romaguerra J, Wang M, et al. Concentrating on Wnt pathway in mantle cell lymphoma-initiating cells. J Hematol Oncol. 2015;8:63.
Kumar A, Sha F, Toure A, Dogan A, Ni A, Batlevi CL, et al. Patterns of survival in sufferers with recurrent mantle cell lymphoma within the fashionable period: progressive shortening in response period and survival after every relapse. Blood Most cancers J. 2019;9:50.
George B, Chowdhury SM, Hart A, Sircar A, Singh SK, Nath UK, et al. Ibrutinib resistance mechanisms and therapy methods for B-Cell lymphomas. Cancers. 2020;12:1328.
Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic focusing on. J Clin Oncol. 2011;29:591–9.
Le Bris Y, Normand A, Bouard L, Menard A, Bossard C, Moreau A, et al. Aggressive, early resistant and relapsed mantle cell lymphoma distinct extrinsic microenvironment highlighted by transcriptome evaluation. EJHaem. 2022;3:1165–71.
Esmeray Sonmez E, Hatipoglu T, Kursun D, Hu X, Akman B, Yuan H, et al. Entire transcriptome sequencing reveals cancer-related, prognostically vital transcripts and tumor-infiltrating immunocytes in mantle cell lymphoma. Cells. 2022;11:3394.
Medina DJ, Goodell L, Glod J, Gelinas C, Rabson AB, Strair RK. Mesenchymal stromal cells defend mantle cell lymphoma cells from spontaneous and drug-induced apoptosis by secretion of B-cell activating issue and activation of the canonical and non-canonical nuclear issue kappaB pathways. Haematologica. 2012;97:1255–63.
Jain P, Nomie Okay, Kotlov N, Segodin V, Hill H, Okay CY, et al. Immune-depleted tumor microenvironment is related to poor outcomes and BTK inhibitor resistance in mantle cell lymphoma. Blood Most cancers J. 2023;13:156.
Sircar A, Singh S, Xu-Monette ZY, Coyle KM, Hilton LK, Chavdoula E, et al. Exploiting the fibroblast development issue receptor-1 vulnerability to therapeutically prohibit the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma. Leukemia. 2023;37:2094–106.
Araujo-Ayala F, Dobano-Lopez C, Valero JG, Nadeu F, Gava F, Faria C, et al. A novel patient-derived 3D mannequin recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses. Leukemia. 2023;37:1311–23.
Sadeghi L, Wright APH. GSK-J4 inhibition of KDM6B histone demethylase blocks adhesion of mantle cell lymphoma cells to stromal cells by modulating NF-kappaB signaling. Cells. 2023;12:2010.
Pandey PR, Younger KH, Kumar D, Jain N. RNA-mediated immunotherapy regulating tumor immune microenvironment: subsequent wave of most cancers therapeutics. Mol Most cancers. 2022;21:58.
Liu L, Wang Q, Qiu Z, Kang Y, Liu J, Ning S, et al. Noncoding RNAs: the shot callers in tumor immune escape. Sign Transduct Goal Ther. 2020;5:102.
Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics—challenges and potential options. Nat Rev Drug Discov. 2021;20:629–51.
Gholami A, Farhadi Okay, Sayyadipour F, Soleimani M, Saba F. Lengthy noncoding RNAs (lncRNAs) in human lymphomas. Genes Dis. 2022;9:900–14.
Khanmohammadi S, Fallahtafti P. Lengthy non-coding RNA as a novel biomarker and therapeutic goal in aggressive B-cell non-Hodgkin lymphoma: A scientific overview. J Cell Mol Med. 2023;27:1928–46.
Hu G, Gupta SK, Troska TP, Nair A, Gupta M. Lengthy non-coding RNA profile in mantle cell lymphoma identifies a practical lncRNA ROR1-AS1 related to EZH2/PRC2 complicated. Oncotarget. 2017;8:80223–34.
Wang X, Sehgal L, Jain N, Khashab T, Mathur R, Samaniego F. LncRNA MALAT1 promotes growth of mantle cell lymphoma by associating with EZH2. J Transl Med. 2016;14:346.
Tao HF, Shen JX, Hou ZW, Chen SY, Su YZ, Fang JL. lncRNA FOXP4‑AS1 predicts poor prognosis and accelerates the development of mantle cell lymphoma by the miR‑423‑5p/NACC1 pathway. Oncol Rep. 2021;45:469–80.
Fan Z, Wang X, Li P, Mei C, Zhang M, Zhao C. Overexpression of lncRNA GATA6-AS inhibits most cancers cell proliferation in mantle cell lymphoma by downregulating GLUT1. Oncol Lett. 2019;18:2443–7.
Tang X, Lengthy Y, Xu L, Yan X. LncRNA MORT inhibits most cancers cell proliferation and promotes apoptosis in mantle cell lymphoma by upregulating miRNA-16. Most cancers Manag Res. 2020;12:2119–25.
Rastad H, Samimisedeh P, Alan MS, Afshar EJ, Ghalami J, Hashemnejad M, et al. The function of lncRNA CERS6-AS1 in most cancers and its molecular mechanisms: a scientific overview and meta-analysis. Pathol Res Pr. 2023;241:154245.
Yun Z, Meng F, Li S, Zhang P. Lengthy non-coding RNA CERS6-AS1 facilitates the oncogenicity of pancreatic ductal adenocarcinoma by regulating the microRNA-15a-5p/FGFR1 axis. Ageing (Albany NY). 2021;13:6041–54.
Xu J, Wang J, He Z, Chen P, Jiang X, Chen Y, et al. LncRNA CERS6-AS1 promotes proliferation and metastasis by the upregulation of YWHAG and activation of ERK signaling in pancreatic most cancers. Cell Dying Dis. 2021;12:648.
Xu B, Wei Y, Liu F, Li L, Zhou S, Peng Y, et al. Lengthy noncoding RNA CERS6-AS1 modulates glucose metabolism and tumor development in hepatocellular carcinoma by selling the MDM2/p53 signaling pathway. Cell Dying Discov. 2022;8:348.
Li Z, Liu X, Luo N, Pang Y, Hou Y, Jiang G. Lengthy non-coding RNA CERS6-AS1 performs a prognostic function in selling the development of gastric most cancers. Bioengineered. 2021;12:12931–9.
Zhao SY, Wang Z, Wu XB, Zhang S, Chen Q, Wang DD, et al. CERS6-AS1 contributes to the malignant phenotypes of colorectal most cancers cells by interacting with miR-15b-5p to manage SPTBN2. Kaohsiung J Med Sci. 2022;38:403–14.
Cabaret O, Perron E, Bressac-de Paillerets B, Soufir N, de la Fouchardiere A. Prevalence of BAP1 germline mutations in cutaneous melanocytic tumors with lack of BAP1-expression: a pilot examine. Genes Chromosomes Most cancers. 2017;56:691–4.
Gao KF, Zhao YF, Liao WJ, Xu GL, Zhang JD. CERS6-AS1 promotes cell proliferation and represses cell apoptosis in pancreatic most cancers through miR-195-5p/WIPI2 axis. Kaohsiung J Med Sci. 2022;38:542–53.
Bao G, Huang J, Pan W, Li X, Zhou T. Lengthy noncoding RNA CERS6-AS1 capabilities as a malignancy promoter in breast most cancers by binding to IGF2BP3 to boost the steadiness of CERS6 mRNA. Most cancers Med. 2020;9:278–89.
Medina DJ, Abass-Shereef J, Walton Okay, Goodell L, Aviv H, Strair RK, et al. Cobblestone-area forming cells derived from sufferers with mantle cell lymphoma are enriched for CD133+ tumor-initiating cells. PLoS One. 2014;9:e91042.
Du S, Zhang Y, Xu J. Present progress in most cancers therapy by focusing on FGFR signaling. Most cancers Biol Med. 2023;20:490–9.
Wiedlocha A, Haugsten EM, Zakrzewska M. Roles of the FGF-FGFR signaling system in most cancers growth and irritation. Cells. 2021;10:2231.
Ko J, Meyer AN, Haas M, Donoghue DJ. Characterization of FGFR signaling in prostate most cancers stem cells and inhibition through TKI therapy. Oncotarget. 2021;12:22–36.
Loda A, Calza S, Giacomini A, Ravelli C, Krishna Chandran AM, Tobia C, et al. FGF-trapping hampers most cancers stem-like cells in uveal melanoma. Most cancers Cell Int. 2023;23:89.
Bi Y, Zheng R, Hu J, Shi R, Shi J, Wang Y, et al. A novel FGFR1 inhibitor CYY292 suppresses tumor development, invasion, and metastasis of glioblastoma by inhibiting the Akt/GSK3beta/snail signaling axis. Genes Dis. 2024;11:479–94.
Cheng Q, Ma Z, Shi Y, Parris AB, Kong L, Yang X. FGFR1 overexpression induces most cancers cell stemness and enhanced Akt/Erk-ER signaling to advertise palbociclib resistance in luminal a breast most cancers cells. Cells. 2021;10:3008.
Shaath H, Vishnubalaji R, Elango R, Kardousha A, Islam Z, Qureshi R, et al. Lengthy non-coding RNA and RNA-binding protein interactions in most cancers: Experimental and machine studying approaches. Semin Most cancers Biol. 2022;86:325–45.
Wu R, Li L, Bai Y, Yu B, Xie C, Wu H, et al. The lengthy noncoding RNA LUCAT1 promotes colorectal most cancers cell proliferation by antagonizing Nucleolin to manage MYC expression. Cell Dying Dis. 2020;11:908.
Aguilar-Garrido P, Otero-Sobrino A, Navarro-Aguadero MA, Velasco-Estevez M, Gallardo M. The function of RNA-binding proteins in hematological malignancies. Int J Mol Sci. 2022;23:9552.
Clever JF, Berkova Z, Mathur R, Zhu H, Braun FK, Tao RH, et al. Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo through a floor nucleolin-Fas complicated. Blood. 2013;121:4729–39.
Jain N, Zhu H, Khashab T, Ye Q, George B, Mathur R, et al. Concentrating on nucleolin for higher survival in diffuse giant B-cell lymphoma. Leukemia. 2018;32:663–74.
Carvalho LS, Goncalves N, Fonseca NA, Moreira JN. Most cancers stem cells and nucleolin as drivers of carcinogenesis. Prescribed drugs. 2021;14:60.
Guo Y, Xie Y, Luo Y. The function of lengthy non-coding RNAs within the tumor immune microenvironment. Entrance Immunol. 2022;13:851004.
Pi YN, Qi WC, Xia BR, Lou G, Jin WL. Lengthy non-coding RNAs within the tumor immune microenvironment: organic properties and therapeutic potential. Entrance Immunol. 2021;12:697083.
Zhang J, Lou W. A Key mRNA-miRNA-lncRNA competing endogenous RNA triple sub-network linked to prognosis and prognosis of hepatocellular carcinoma. Entrance Oncol. 2020;10:340.
Zhou C, Chen Y, He X, Zheng Z, Xue D. Useful implication of exosomal miR-217 and miR-23b-3p within the development of prostate most cancers. Onco Targets Ther. 2020;13:11595–606.
Yu H, Pang Z, Li G, Gu T. Bioinformatics evaluation of differentially expressed miRNAs in non-small cell lung most cancers. J Clin Lab Anal. 2021;35:e23588.
Fan YX, Shi HY, Hu YL, Jin XL. Circ_0000144 facilitates the development of thyroid most cancers through the miR-217/AKT3 pathway. J Gene Med. 2020;22:e3269.
Brennan SK, Meade B, Wang Q, Service provider AA, Kowalski J, Matsui W. Mantle cell lymphoma activation enhances bortezomib sensitivity. Blood. 2010;116:4185–91.
Chen Z, Ayala P, Wang M, Fayad L, Katz RL, Romaguera J, et al. Potential isolation of clonogenic mantle cell lymphoma-initiating cells. Stem Cell Res. 2010;5:212–25.
Pattabiraman DR, Weinberg RA. Tackling the most cancers stem cells—what challenges do they pose? Nat Rev Drug Discov. 2014;13:497–512.
Turdo A, Veschi V, Gaggianesi M, Chinnici A, Bianca P, Todaro M, et al. Assembly the problem of focusing on most cancers stem cells. Entrance Cell Dev Biol. 2019;7:16.
Sadeghi L, Arvidsson G, Merrien M, M Wasik A, Görgens A, Smith CIE, et al. Differential B-cell receptor signaling requirement for adhesion of mantle cell lymphoma cells to stromal cells. Cancers. 2020;12:1143.
Pacini L, Jenks AD, Lima NC, Huang PH. Concentrating on the fibroblast development issue receptor (FGFR) household in lung most cancers. Cells. 2021;10:1154.
Bi Y, Zheng R, Hu J, Shi R, Shi J, Wang Y. et al.Corrigendum to “A novel FGFR1 inhibitor CYY292 suppresses tumor development, invasion, and metastasis of glioblastoma by inhibiting the Akt/GSK3beta/snail signaling axis” [Genes & Diseases 11 (2024) 479-494].Genes Dis. 2024;11:101168.
Dhangar S, Shanmukhaiah C, Sawant L, Ghatanatti J, Shah A, Mathan SL, et al. Synergetic impact of Azacitidine and Sorafenib in therapy of a case of myeloid neoplasm with sole chromosomal abnormality t(8;22)(p11.2;q11.2)/BCR-FGFR1 rearrangement. Most cancers Genet. 2023;274-275:26–9.
Yamamoto T, Miyoshi H, Kakizaki F, Maekawa H, Yamaura T, Morimoto T, et al. Chemosensitivity of patient-derived most cancers stem cells identifies colorectal most cancers sufferers with potential profit from FGFR inhibitor remedy. Cancers. 2020;12:2010.
Feng W, Gao M, Yang M, Li X, Gan Z, Wu T, et al. TNFAIP3 promotes ALDH-positive breast most cancers stem cells by FGFR1/MEK/ERK pathway. Med Oncol. 2022;39:230.
Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, et al. Metabolic reprogramming towards oxidative phosphorylation identifies a therapeutic goal for mantle cell lymphoma. Sci Transl Med. 2019;11:eaau1167.
Thongchot S, Aksonnam Okay, Thuwajit P, Yenchitsomanus PT, Thuwajit C. Nucleolin‑primarily based focusing on methods in most cancers therapy: Deal with most cancers immunotherapy (Assessment). Int J Mol Med. 2023;52:81.
Romano S, Fonseca N, Simoes S, Goncalves J, Moreira JN. Nucleolin-based focusing on methods for most cancers remedy: from focused drug supply to cytotoxic ligands. Drug Discov Right this moment. 2019;24:1985–2001.
Ferrara B, Belbekhouche S, Habert D, Houppe C, Vallee B, Bourgoin-Voillard S, et al. Cell floor nucleolin as energetic bait for nanomedicine in most cancers remedy: a promising choice. Nanotechnology. 2021;32:322001.
Yan L, Li Okay, Feng Z, Zhang Y, Han R, Ma J, et al. lncRNA CERS6-AS1 as ceRNA promote cell proliferation of breast most cancers by sponging miR-125a-5p to upregulate BAP1 expression. Mol Carcinog. 2020;59:1199–208.
Yangngam S, Prasopsiri J, Hatthakarnkul P, Thongchot S, Thuwajit P, Yenchitsomanus PT, et al. Mobile localization of nucleolin determines the prognosis in cancers: a meta-analysis. J Mol Med. 2022;100:1145–57.
Chen J, Guo Okay, Kastan MB. Interactions of nucleolin and ribosomal protein L26 (RPL26) in translational management of human p53 mRNA. J Biol Chem. 2012;287:16467–76.
Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N, Fernandes DJ. The nucleolin focusing on aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast most cancers cells. Most cancers Res. 2008;68:2358–65.
Otake Y, Soundararajan S, Sengupta TK, Kio EA, Smith JC, Pineda-Roman M, et al. Overexpression of nucleolin in continual lymphocytic leukemia cells induces stabilization of bcl2 mRNA. Blood. 2007;109:3069–75.
Allain FH, Bouvet P, Dieckmann T, Feigon J. Molecular foundation of sequence-specific recognition of pre-ribosomal RNA by nucleolin. EMBO J. 2000;19:6870–81.
